Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Open Access
- 9 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 13 (1), 1-16
- https://doi.org/10.1186/s13045-020-00896-0
Abstract
Melanoma patients who have detectable serum soluble NKG2D ligands either at the baseline or post-treatment of PD1/PDL1 blockade exhibit poor overall survival. Among families of soluble human NKG2D ligands, the soluble human MHC I chain-related molecule (sMIC) was found to be elevated in melanoma patients and mostly associated with poor response to PD1/PDL1 blockade therapy. In this study, we aim to investigate whether co-targeting tumor-released sMIC enhances the therapeutic outcome of PD1/PDL1 blockade therapy for melanoma. We implanted sMIC-expressing B16F10 melanoma tumors into syngeneic host and evaluated therapeutic efficacy of anti-sMIC antibody and anti-PDL1 antibody combination therapy in comparison with monotherapy. We analyzed associated effector mechanism. We also assessed sMIC/MIC prevalence in metastatic human melanoma tumors. We found that the combination therapy of the anti-PDL1 antibody with an antibody targeting sMIC significantly improved animal survival as compared to monotherapies and that the effect of combination therapy depends significantly on NK cells. We show that combination therapy significantly increased IL-2Rα (CD25) on NK cells which sensitizes NK cells to low dose IL-2 for survival. We demonstrate that sMIC negatively reprograms gene expression related to NK cell homeostatic survival and proliferation and that antibody clearing sMIC reverses the effect of sMIC and reprograms NK cell for survival. We further show that sMIC/MIC is abundantly present in metastatic human melanoma tumors. Our findings provide a pre-clinical proof-of-concept and a new mechanistic understanding to underscore the significance of antibody targeting sMIC to improve therapeutic efficacy of anti-PD1/PDL1 antibody for MIC/sMIC+ metastatic melanoma patients.Keywords
Funding Information
- National Institutes of Health (1R01CA208246, 1R01CA204021)
This publication has 58 references indexed in Scilit:
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasisJCI Insight, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational studyBMC Cancer, 2012
- NKG2D Initiates Caspase-Mediated CD3ζ Degradation and Lymphocyte Receptor Impairments Associated with Human Cancer and Autoimmune DiseaseThe Journal of Immunology, 2010
- ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patientsInternational Journal of Cancer, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2008
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorNature, 2005
- Roles of the NKG2D immunoreceptor and its ligandsNature Reviews Immunology, 2003